Literature DB >> 11998896

Correlations of soluble interleukin-2 and tumor necrosis factor type II receptors with immunologic and virologic responses under HAART.

F Bonnet1, M Savès, P H Morlat, C Droz, G Chêne, E Peuchant, N Bernard, D Lacoste, R Salamon, J Beylot.   

Abstract

We assessed the correlations between some plasma markers of immune activation (soluble receptors of interleukin 2 (sIL2-R) and TNFap75 (sTNFII-R) and usual markers of HIV infection in patients treated with protease-inhibitors (PI). Forty-six PI-naive HIV-1-infected adults were included in a 1-year prospective cohort from the initiation of a P1-containing regimen (M0). Measurements of CD4+cell count, plasma HIV-RNA, sIL2-R and sTNFII-R were performed at M0, M6, and M12. The evolution of sIL2-R from baseline to M12 was significantly different between immunological responders (IR) (CD4+count above 200/mm3 for subject having less than 200 CD4 +/mm3 at inclusion, or increase of at least 50 CD4+/mm3 for others) (58 UI/ml) and non-IR (+28 UI/ml) (P =0.01). The evolution of sTNFII-R between M0 and M12 was significantly different between virological responders (VR) (plasma HIV-1 RNA less than 500 copies/ml at M12) (-2.5 ng/ml) and non-VR (+0.2 ng/ml) (P = 0.02). Our study shows significative correlations between the evolutions of soluble interleukin-2 and TNFR-II receptors and those of CD4+T-lymphocytes or HIV-RNA responses in patients under HAART.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11998896     DOI: 10.1023/a:1014475618504

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  24 in total

1.  Cytokines and HIV infection: is AIDS a tumor necrosis factor disease?

Authors:  T Matsuyama; N Kobayashi; N Yamamoto
Journal:  AIDS       Date:  1991-12       Impact factor: 4.177

2.  Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team.

Authors:  M D Hughes; V A Johnson; M S Hirsch; J W Bremer; T Elbeik; A Erice; D R Kuritzkes; W A Scott; S A Spector; N Basgoz; M A Fischl; R T D'Aquila
Journal:  Ann Intern Med       Date:  1997-06-15       Impact factor: 25.391

3.  Interleukin-1 and tumor necrosis factor alpha can be induced from mononuclear phagocytes by human immunodeficiency virus type 1 binding to the CD4 receptor.

Authors:  J E Merrill; Y Koyanagi; I S Chen
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

4.  HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy.

Authors:  G M Ortiz; D F Nixon; A Trkola; J Binley; X Jin; S Bonhoeffer; P J Kuebler; S M Donahoe; M A Demoitie; W M Kakimoto; T Ketas; B Clas; J J Heymann; L Zhang; Y Cao; A Hurley; J P Moore; D D Ho; M Markowitz
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

5.  Cytocidal effect of tumor necrosis factor on cells chronically infected with human immunodeficiency virus (HIV): enhancement of HIV replication.

Authors:  T Matsuyama; Y Hamamoto; G Soma; D Mizuno; N Yamamoto; N Kobayashi
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

6.  Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.

Authors:  J M Jacobson; J S Greenspan; J Spritzler; N Ketter; J L Fahey; J B Jackson; L Fox; M Chernoff; A W Wu; L A MacPhail; G J Vasquez; D A Wohl
Journal:  N Engl J Med       Date:  1997-05-22       Impact factor: 91.245

7.  Soluble IL-2 receptor and tumour necrosis factor-alpha in plasma of haemophilia patients infected with HIV.

Authors:  I L Noronha; V Daniel; K Schimpf; G Opelz
Journal:  Clin Exp Immunol       Date:  1992-02       Impact factor: 4.330

8.  The effect of acute infectious illnesses on plasma human immunodeficiency virus (HIV) type 1 load and the expression of serologic markers of immune activation among HIV-infected adults.

Authors:  M S Sulkowski; R E Chaisson; C L Karp; R D Moore; J B Margolick; T C Quinn
Journal:  J Infect Dis       Date:  1998-12       Impact factor: 5.226

9.  The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.

Authors:  J L Fahey; J M Taylor; R Detels; B Hofmann; R Melmed; P Nishanian; J V Giorgi
Journal:  N Engl J Med       Date:  1990-01-18       Impact factor: 91.245

10.  HIV-1 Tat potentiates TNF-induced NF-kappa B activation and cytotoxicity by altering the cellular redox state.

Authors:  M O Westendorp; V A Shatrov; K Schulze-Osthoff; R Frank; M Kraft; M Los; P H Krammer; W Dröge; V Lehmann
Journal:  EMBO J       Date:  1995-02-01       Impact factor: 11.598

View more
  2 in total

1.  Characterization of plasmablasts in the blood of HIV-infected viremic individuals: evidence for nonspecific immune activation.

Authors:  Clarisa M Buckner; Susan Moir; Jason Ho; Wei Wang; Jacqueline G Posada; Lela Kardava; Emily K Funk; Amy K Nelson; Yuxing Li; Tae-Wook Chun; Anthony S Fauci
Journal:  J Virol       Date:  2013-03-13       Impact factor: 5.103

2.  Utility of Serum Neopterin and Serum IL-2 Receptor Levels to Predict Absolute CD4 T Lymphocyte Count in HIV Infected Cases.

Authors:  Sanjim Chadha; Preena Bhalla; Hitender Gautam; Anita Chakravarti; Sanjeev Saini; S Anuradha; Richa Dewan
Journal:  Interdiscip Perspect Infect Dis       Date:  2013-12-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.